Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant pembrolizumab with or without MK-2870 in resectable NSCLC without pCR after neoadjuvant pembrolizumab plus platinum-doublet chemotherapy and surgery
MOH_2024-03-26_013152Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant pembrolizumab + MK-2870 with Adjuvant pembrolizumab monotherapy (2 arms). Primary endpoint: Disease-free survival. Started Mar 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-03-26_013152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-26_013152.